Loading organizations...
Bixink Therapeutics develops and commercializes a dual portfolio of cancer therapeutics and digital health solutions. Its oncology offerings include anti-cancer treatments like Nerlynx®, complemented by digital cognitive behavioral therapies such as OC Free®. This approach leverages both pharmaceutical and innovative digital technologies to deliver comprehensive patient care.
Established in Seoul, South Korea, in 2016, Bixink was founded on the insight that combining advanced pharmacology with accessible digital health solutions would significantly enhance patient outcomes. The company's inception reflects a strategic vision to address critical health challenges by diversifying therapeutic options beyond traditional boundaries.
Bixink's products cater to patients requiring specialized cancer treatments and individuals seeking digital support for health conditions. The company envisions becoming a leader in integrated healthcare, continually expanding its offerings to meet diverse global patient needs. Bixink strives to empower patients with effective, accessible, and innovative tools for improved well-being.
Bixink has 2 tracked investments across 1 company. The latest tracked deal is $15.0M Series A in Limbix in December 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2021 | Limbix | $15.0M Series A | GSR Ventures | Digital Garage, DN Capital, E& Capital, Gaingels, Korea Investment Partners, Mana Ventures, MVP Ventures, Operator Partners, Pacific Health Ventures, Storm Ventures |
| May 1, 2020 | Limbix | $9.0M Series A | GSR Ventures | DST Global, GE Ventures, Andrew Wheeler, Marc VAN DEN Berg, Sequoia Capital, UP.Partners, RON Pragides, NextGen Venture Partners, Storm Ventures |
